Novo Nordisk Launches 'Rare Disease Division'

[Asia Economy Reporter Lee Chun-hee] Novo Nordisk Korea announced on the 7th that it is officially entering the rare disease sector by renaming its existing biopharm division to the "Rare Disease Division."

This division name change was made at the global level of Novo Nordisk to expand from the previously focused disease areas such as hemophilia and growth disorders to include research and development (R&D) of treatments for rare and ultra-rare blood, endocrine, and kidney diseases. Additionally, the company plans to seek solutions to unmet needs in related diseases through innovative technology and data digitalization.

Ludovic Helfgott, Vice President of Global Rare Diseases at Novo Nordisk, said, "Novo Nordisk's goal is to find new solutions for rare diseases with limited treatment options and to dedicate ourselves to people living with rare diseases." He added, "To this end, we are accelerating innovative technologies and researching various new technologies that can provide new options for rare disease treatment." He further explained, "Recently, through the acquisition of Diserna, we have partnered with 270 biotech companies and are focusing more on direct investment in new technologies."

Accordingly, Novo Nordisk Korea will also begin full-scale activities as a rare disease division. As part of this, on the 7th, it held a rare disease education session for internal employees to provide information on rare and ultra-rare diseases in commemoration of World Rare Disease Day.

Rana Azfa Jafa, President of Novo Nordisk Korea, said, "The new launch of the Rare Disease Division and the expansion into the rare disease sector demonstrate our commitment to delivering integrated treatment solutions from diagnosis to rare disease management by further strengthening our unique expertise." She added, "We will strive in various ways to reinforce the belief that patients with rare diseases in Korean society can be healthy."

This content was produced with the assistance of AI translation services.